Where Does The Chemours Company (CC) Stock Go From Here?

Patrice Gainsbourg
Julho 17, 2017

Institutional investors own 75.01% of the company's stock. Finally, Teachers Advisors LLC raised its position in Chemours Company (The) by 2.5% in the fourth quarter.

The Chemours Company's average Book Value per Share Growth Rate was 84.7 percent during the past 12 months. Jefferies raised its rating on The Chemours Company to Buy on 29/03/2017 in a reversal from its prior Hold rating.

Analyst research firms are expressing bullish stance on The Chemours Company (NYSE:CC)'s near-term growth potential.

Beta is also an important valuation ratio for analyzing the stock of the company, CC has Beta of 0 while its industry and Sector's beta remains at 0.27 and 0.9 respectively. The ex-dividend date of this dividend was Monday, May 15th. Chemours Company has a 1-year low of $5.82 and a 1-year high of $46.02. They now have $45.00 price target on the specialty chemicals company's stock, up from their prior price target of $43.00. The firm had revenue of $1.44 billion for the quarter, compared to analysts' expectations of $1.32 billion. One research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company's stock. Jefferies Group LLC reissued a "buy" rating and issued a $50.00 price objective (up from $48.00) on shares of Chemours Company (The) in a report on Thursday. Ropes Wealth Advisors LLC now owns 3,099 shares of the specialty chemicals company's stock valued at $119,000 after buying an additional 1,400 shares during the last quarter. Charter Trust Co. acquired a new position in Chemours Company (The) during the first quarter valued at $215,000. The market capitalization of the company is at $8.03 Billion. Cypress Capital Management LLC WY now owns 4,196 shares of the specialty chemicals company's stock valued at $162,000 after buying an additional 80 shares during the last quarter.

Chemours Company (CC) opened at 40.09 on Monday. The firm owned 34,200 shares of the specialty chemicals company's stock after selling 63,030 shares during the period. The Average Volume of the company is 3.07 Million, while the Volume of the company in the last trading session was 2.17 Billion. The analysts estimated EPS for the higher end at 0.99 and lower end at 0.88 while the year ago reported earnings per share was 0.33. Vanguard Group Inc. raised its position in shares of Chemours Company (The) by 1.2% in the first quarter. Chemours Company (The) had a return on equity of 125.69% and a net margin of 1.91%. During the same period a year ago, the company posted $0.06 earnings per share. The Chemours Company (NYSE:CC) is 46.65% above its 200-day moving average, providing a measure of resistance for long positions.

Jana granted regulatory clearance for Zimmer Biomet stake
First Allied Advisory Services Inc. raised its position in shares of Zimmer Biomet Holdings by 70.6% in the fourth quarter. The company had revenue of $1.98 billion during the quarter, compared to analysts' expectations of $1.96 billion.

Quarterly Revenue growth year over year is 10.8 Percent.

WARNING: This piece of content was originally published by The Cerbat Gem and is the property of of The Cerbat Gem.

Several hedge funds and other institutional investors have recently bought and sold shares of CC. If you are reading this piece on another website, it was illegally copied and republished in violation of United States & worldwide copyright laws. This represents a $0.12 annualized dividend and a yield of 0.28%. The original version of this piece can be read at https://www.thestockobserver.com/2017/07/14/chemours-company-the-cc-earning-positive-media-coverage-study-finds.html. President - Fluoroproducts Paul Kirsch sold 19,036 shares at an average price of $41.42 on Monday the 5th. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Richard H. Brown acquired 2,500 shares of the firm's stock in a transaction on Wednesday, May 3rd. The shares were purchased at an average price of $39.10 per share, for a total transaction of $97,750.00. The shares were sold at an average price of $41.42, for a total transaction of $788,471.12. The disclosure for this purchase can be found here.

The Chemours Company is a provider of performance chemicals. The Titanium Technologies segment is a producer of titanium dioxide (TiO2).

Other large investors have also recently made changes to their positions in the company. The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Outros relatórios LazerEsportes

Discuta este artigo